Cover Image
市場調查報告書

骨關節炎疼痛治療藥的全球市場:2016年∼2020年

Global Osteoarthritis Pain Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 358381
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
骨關節炎疼痛治療藥的全球市場:2016年∼2020年 Global Osteoarthritis Pain Market 2016-2020
出版日期: 2016年05月16日 內容資訊: 英文 97 Pages
簡介

全球骨關節炎疼痛治療藥市場在2016年∼2020年間預測將以年複合成長率 (CAGR) 8.38%的速度成長。

本報告提供全球骨關節炎疼痛治療藥市場相關調查分析,提供您市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

第1章 摘要整理

  • 焦點

第2章 調查範圍

  • 市場概要
  • 前提條件
  • 主要供應商產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 主要市場焦點
  • 主要的購買標準

第5章 疾病概要

  • 關於骨關節炎
  • 病因·病理生理學
  • 危險因素
  • 徵兆與症狀
  • 診斷
  • 疾病管理
  • 外科治療
  • 流行病學
  • 骨關節炎的經濟負擔

第6章 產品研發線

  • 開發平台候補相關資訊
  • Ampion
  • Tanezumab
  • Zilretta (FX006)
  • Fasinumab
  • IP 880
  • SoluMatrix Naproxen
  • ABT-981
  • AF-219
  • ASP7962

第7章 骨關節炎疼痛治療藥:臨床實驗

第8章 骨關節炎的研究的機會

第9章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第10章 市場區隔:各類藥物

  • 非類固醇系抗發炎藥 (NSAID)
  • 類鴉片物質
  • 關節內補充藥
  • 皮質類固醇
  • 其他

第11章 市場區隔:各給藥途徑

  • 口服
  • 非口服
  • 局部

第12章 市場區隔:各劑型

  • 固體
  • 液體
  • 半固體

第13章 地理位置區分

  • 南北美洲
  • 美國
  • 歐洲·中東·非洲
  • 亞太地區

第14章 推動市場要素

第15章 推動因素的影響

第16章 市場課題

第17章 推動因素與課題的影響

第18章 市場趨勢

第19章 業者情勢

  • 競爭模式
  • Abbott Laboratories
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • 其他卓越供應商

第20章 由於新的方法的未來供應商

  • Ampio Pharmaceuticals
  • Flexion Therapeutics
  • Kitov Pharmaceuticals

第21章 附錄

  • 簡稱清單

第22章 關於Technavio

圖表

目錄
Product Code: IRTNTR9464

About the Osteoarthritis Pain Drugs Market

Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement. It is also known as degenerative joint disease, hypertrophic arthritis, and degenerative arthritis, and is most commonly prevalent in older (above 60 years of age) and middle-aged people (between 40-59 years of age). The exact etiology of osteoarthritis is not well understood, but is believed to be an outcome of mechanical and molecular events in the affected joint. Increasing age, obesity, overuse of the joint, weak thigh muscles, and genetics are some of the common risk factors. Treatment is given depending upon the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise.

Technavio's analysts forecast the global osteoarthritis pain drugs market to grow at a CAGR of 8.38% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global osteoarthritis pain drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat osteoarthritis pain. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Osteoarthritis Pain Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Abbott Laboratories
  • Johnson & Johnson
  • Novartis International
  • Pfizer

Other Prominent Vendors

  • AbbVie
  • Abiogen Pharma
  • Afferent Pharmaceuticals
  • Astellas Pharma
  • BioDelivery Sciences International
  • Crystal Genomics
  • Cytori Therapeutics
  • Daiichi Sankyo
  • Eli Lilly
  • Endo Pharmaceuticals Holdings
  • Horizon Pharma
  • iCeutica
  • Iroko Pharmaceuticals
  • Merck
  • Nuvo Research
  • Regeneron Pharmaceuticals
  • Sanofi
  • SantoSolve
  • Techfields Pharma
  • Winston Pharmaceuticals
  • Yooyoung Pharmaceutical
  • Zynerba Pharmaceuticals

Market driver

  • Significant unmet medical needs
  • For a full, detailed list, view our report

Market challenge

  • Preference for alternative therapies
  • For a full, detailed list, view our report

Market trend

  • Emergence of new treatments
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Assumptions
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Disease overview

  • Understanding osteoarthritis
  • Etiology and pathophysiology
  • Risk factors
  • Signs and symptoms
  • Diagnosis
  • Disease management
  • Surgical treatment
  • Epidemiology
  • Economic burden of osteoarthritis

PART 06: Pipeline portfolio

  • Information on pipeline candidates
  • Ampion
  • Tanezumab
  • Zilretta (FX006)
  • Fasinumab
  • IP 880
  • SoluMatrix Naproxen
  • ABT-981
  • AF-219
  • ASP7962

PART 07: Osteoarthritis pain drugs: Clinical trials

PART 08: Opportunities for research in osteoarthritis

  • Gaps between current research and possible research issues
  • Challenges for vendors involved in osteoarthritis drug development

PART 09: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 10: Market segmentation by drug class

  • NSAIDs
  • Opioids
  • Viscosupplements
  • Corticosteroids
  • Others
  • Global NSAIDs market
  • Global opioids market
  • Global viscosupplements market
  • Global corticosteroids market

PART 11: Market segmentation by ROA

  • Oral
  • Parenteral
  • Topical

PART 12: Market segmentation by dosage form

  • Solid
  • Liquid
  • Semi-solid

PART 13: Geographical segmentation

  • Osteoarthritis pain drugs market in Americas
  • Osteoarthritis pain drugs market in US
  • Osteoarthritis pain drugs market in EMEA
  • Osteoarthritis pain drugs market in APAC

PART 14: Market drivers

  • Significant unmet medical needs
  • Promising drug pipeline
  • Increase in prevalence of osteoarthritis and obesity

PART 15: Impact of drivers

PART 16: Market challenges

  • Preference for alternative therapies
  • Loss of patent exclusivity of branded therapies
  • Adverse effects of drugs

PART 17: Impact of drivers and challenges

PART 18: Market trends

  • Emergence of new treatments
  • Use of off-label drugs
  • Strategic alliances

PART 19: Vendor landscape

  • Competitive scenario
  • Abbott Laboratories
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Other prominent vendors

PART 20: Upcoming vendors with novel approaches

  • Ampio Pharmaceuticals
  • Flexion Therapeutics
  • Kitov Pharmaceuticals

PART 21: Appendix

  • List of abbreviations

PART 22: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria
  • Exhibit 03: Types of osteoarthritis
  • Exhibit 04: Etiology and pathophysiology of osteoarthritis
  • Exhibit 05: Signs and symptoms of osteoarthritis
  • Exhibit 06: Diagnostic test for osteoarthritis
  • Exhibit 07: Treatment options for osteoarthritis
  • Exhibit 08: Non-pharmacological therapies used for osteoarthritis
  • Exhibit 09: Pharmacotherapy therapy for osteoarthritis
  • Exhibit 10: Surgical treatment
  • Exhibit 11: Economic burden of osteoarthritis
  • Exhibit 12: Distribution of direct costs of osteoarthritis
  • Exhibit 13: Cost analysis of treatment for individuals with osteoarthritis
  • Exhibit 14: Pipeline molecules for osteoarthritis pain
  • Exhibit 15: Osteoarthritis clinical trials by development phase
  • Exhibit 16: Share of Phase I, II, and III pipeline candidates in osteoarthritis pain drugs market
  • Exhibit 17: Osteoarthritis clinical trials by trial status
  • Exhibit 18: Highlights of osteoarthritis research opportunities:
  • Exhibit 19: Global osteoarthritis pain drugs market 2015-2020 ($ billions)
  • Exhibit 20: Current opportunities of osteoarthritis industry
  • Exhibit 21: Five forces analysis
  • Exhibit 22: Global osteoarthritis pain drugs market segmentation by drug class
  • Exhibit 23: Some NSAIDs used to treat osteoarthritis pain
  • Exhibit 24: Global osteoarthritis pain drugs market shares by drug class 2015
  • Exhibit 25: Global osteoarthritis pain drugs market segmentation by drug class 2015-2020 ($ billions)
  • Exhibit 26: Global osteoarthritis pain drugs market segmentation by drug class 2015-2020 percentage)
  • Exhibit 27: Global osteoarthritis pain drugs market 2015-2020
  • Exhibit 28: YoY growth rate of global osteoarthritis pain drugs market segments 2015-2020
  • Exhibit 29: Global NSAIDs market 2015-2020 ($ billions)
  • Exhibit 30: Global opioids market 2015-2020 ($ billions)
  • Exhibit 31: Global viscosupplements market 2015-2020 ($ billions)
  • Exhibit 32: Global corticosteroids market 2015-2020 ($ billions)
  • Exhibit 33: Global osteoarthritis pain drugs market segmentation by ROA
  • Exhibit 34: Global osteoarthritis pain drugs market segmentation by ROA 2015
  • Exhibit 35: Global osteoarthritis pain drugs market segmentation by dosage form
  • Exhibit 36: Global osteoarthritis pain drugs market segmentation by ROA 2015
  • Exhibit 37: Global osteoarthritis pain drugs market by geographical segmentation 2015
  • Exhibit 38: Global osteoarthritis pain drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 39: Global osteoarthritis pain drugs market revenue by geography 2015-2020
  • Exhibit 40: Global osteoarthritis pain drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
  • Exhibit 41: Osteoarthritis pain drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 42: Osteoarthritis pain drugs market in Americas 2015
  • Exhibit 43: Osteoarthritis pain drugs market in US 2015-2020 ($ billions)
  • Exhibit 44: Osteoarthritis pain drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 45: Osteoarthritis pain drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 46: Unmet medical needs with current osteoarthritis pain treatments
  • Exhibit 47: Prevalence of osteoarthritis in 2012 and 2022 (millions)
  • Exhibit 48: Average annual prevalence of osteoarthritis in US
  • Exhibit 49: Incidence of osteoarthritis in overweight and normal weight individuals 2013
  • Exhibit 50: Worldwide estimated osteoarthritis population growth 2010-2020
  • Exhibit 51: Population aged 60 years and over: World, developed, and developing regions (millions)
  • Exhibit 52: Expected growth of older population in US 2010-2050
  • Exhibit 53: Impact of drivers
  • Exhibit 54: Alternative therapies for osteoarthritis pain
  • Exhibit 55: Use of CAM therapies among individuals in US
  • Exhibit 56: Impact of drivers and challenges
  • Exhibit 57: Future therapeutics in osteoarthritis pain treatment
  • Exhibit 58: Key takeaways
  • Exhibit 59: Key takeaways
  • Exhibit 60: Novartis: YoY revenue and growth rate of Voltaren 2013-2015 ($ millions)
  • Exhibit 61: Key takeaways
  • Exhibit 62: Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ millions)
  • Exhibit 63: Pfizer: Geographical segmentation of Celebrex 2015
  • Exhibit 64: Key takeaways
  • Exhibit 65: Flexion Therapeutics: Pipeline products
  • Exhibit 66: Kitov Pharmaceuticals: Pipeline products
  • Exhibit 67: Osteoarthritis pain market size model
Back to Top